The bear case on Eli Lilly has played out, says only firm to have called it a sell
Short excerpt below. Click through to read at the original source.
The bear case for Eli Lilly has now played out following the reaction to the drugmaker’s oral obesity drug trial, an analyst said Wednesday in upgrading the stock.